

Norgine, Korea Pharma ink deal to commercialise PLENVU in Korea

08 January 2019 | News

PLENVU is a lower-volume (1L) polyethylene glycol (PEG) based bowel preparation for colonoscopy in adults



NORGINE B.V. (Norgine), a leading European specialty pharmaceutical company and KOREA PHARMA CO., LTD. (Korea Pharma), a premier pharmaceutical manufacturer in Korea, today announced an exclusive license and distribution agreement in the Republic of Korea by which Korea Pharma will commercialize Norgine's product PLENVU.

PLENVU is a lower-volume (1L) polyethylene glycol (PEG) based bowel preparation for colonoscopy in adults. It is the first lower-volume bowel preparation to show superior segmental cleansing of the colon vs. standard of care.

Jae-Don Park, CEO and Chairman of Korea Pharma said, *"Building on our strong presence and knowledge in the South Korea market, we look forward to making PLENVU available to healthcare professionals to help them to improve colonoscopy outcomes as well as patient experience and adherence to bowel cleansing instructions."*

"We are excited about our collaboration with Korea Pharma, a trusted player," said **Peter Stein, Chairman and Chief Executive Officer of Norgine**. *"South Korea is an important market and this partnership reflects the breadth and scope of Norgine's capabilities to build a strong network and reach out to more patients worldwide."*

PLENVU is currently available in mainland Europe (except France and Sweden) and Australia via Norgine and in the USA via its partner Salix Pharmaceuticals.